Sanofi Launches Canada’s Largest Biomanufacturing Facility in Ontario, Boosting Vaccine Production
TORONTO – In a significant stride towards enhancing domestic healthcare infrastructure, Sanofi unveiled Canada’s largest biomanufacturing facility today in Ontario. The grand opening ceremony, attended by government officials and industry leaders, marked a pivotal moment in the nation’s efforts to bolster vaccine production and supply.
Spanning an impressive 200,000 square feet, the state-of-the-art facility, located at Sanofi’s Toronto campus, represents an $800 million investment in advancing life-saving vaccine manufacturing. This landmark initiative is poised to significantly increase the production capacity of crucial pediatric and adult vaccines for pertussis (whooping cough), diphtheria, and tetanus.
Premier Doug Ford, speaking at the inauguration, expressed his satisfaction with the collaboration between the Ontario government and Sanofi. “This new state-of-the-art facility is another vote of confidence in our workers and our growing life sciences sector, helping to ensure people in Ontario and around the world have increased access to life-saving vaccines when they need them,” said Premier Ford.
With 200 employees set to join the workforce, this expansion further solidifies Sanofi’s position as a key player in Ontario’s vibrant life sciences ecosystem. The facility is also supported by federal, municipal, and provincial governments, with Ontario contributing a notable $50 million investment towards its development.
Minister of Economic Development, Job Creation and Trade, Vic Fedeli, hailed the facility as a strategic asset to Ontario’s biomanufacturing supply chain. “Sanofi’s new facility represents a strategic link in our province’s biomanufacturing supply chain and is a welcomed addition to Ontario’s growing life sciences ecosystem — the largest in the country,” stated Minister Fedeli.
In addition to the vaccine manufacturing facility, Sanofi is concurrently constructing a second facility on its Toronto campus. This facility will focus on scaling up production of the Fluzone High-Dose Influenza Vaccine, catering specifically to individuals aged 65 and older.
Deputy Premier and Minister of Health, Sylvia Jones, emphasized the broader impact of this development on public health. “Sanofi’s new state-of-the-art vaccine manufacturing facility in Toronto is championing made-in-Ontario vaccinations that will build healthier communities in our province, and around the world, for years to come,” stated Minister Jones.
This milestone aligns with the government’s broader life sciences strategy, which includes significant investments to position Ontario as a global hub for biomanufacturing and life sciences. Over the past three years, Ontario has attracted over $3 billion in investments from life sciences companies and global biomanufacturers.
As Ontario continues to prioritize healthcare innovation and accessibility, the inauguration of Sanofi’s biomanufacturing facility stands as a testament to the province’s commitment to advancing public health and driving economic growth in the life sciences sector.
For further updates and developments, stay tuned to GTA Today.
